Get the Stockscreener App
10.96
12.64%
+1.2299
After Hours:
10.475
-0.485
-4.43%
Newamsterdam Pharma Company N V stock is currently priced at $10.96, with a 24-hour trading volume of 542.
It has seen a +12.64% increased in the last 24 hours and a +6.41% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $9.73 pivot point. If it approaches the $9.73 resistance level, significant changes may occur.
Previous Close:
$9.7301
Open:
$11
24h Volume:
542
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+12.64%
1M Performance:
+6.41%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1D Range:
$10.96
$11.00
52W Range:
$2.60
$14.67
Newamsterdam Pharma Company N V Stock (NAMSW) Company Profile
Name
Newamsterdam Pharma Company N V
Sector
Industry
Phone
31 35 206 2971
Address
Gooimeer 2-35, Naarden
Newamsterdam Pharma Company N V Stock (NAMSW) Latest News
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
GlobeNewswire Inc.
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
GlobeNewswire Inc.
NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
GlobeNewswire Inc.
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
GlobeNewswire Inc.
NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
GlobeNewswire Inc.
Newamsterdam Pharma Company N V Stock (NAMSW) Financials Data
There is no financial data for Newamsterdam Pharma Company N V (NAMSW). Check out other stocks for more information.
About Newamsterdam Pharma Company N V
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
1.62%
0.15%
Cap:
|
Volume (24h):